Molecules 2012, 17(2), 2030-2048; doi:10.3390/molecules17022030
Review

Astaxanthin in Cardiovascular Health and Disease

1,2,3,†,* email and 3,†email
1 School of Medicine, The University of Queensland, Brisbane, Queensland, 4000, Australia 2 Department of Renal Medicine, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, 4029, Australia 3 The School of Human Movement Studies, The University of Queensland, St Lucia, Queensland, 4072, Australia These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 18 January 2012; in revised form: 13 February 2012 / Accepted: 13 February 2012 / Published: 20 February 2012
(This article belongs to the Special Issue Carotenoids)
PDF Full-text Download PDF Full-Text [289 KB, uploaded 20 February 2012 09:14 CET]
Abstract: Oxidative stress and inflammation are established processes contributing to cardiovascular disease caused by atherosclerosis. However, antioxidant therapies tested in cardiovascular disease such as vitamin E, C and β-carotene have proved unsuccessful at reducing cardiovascular events and mortality. Although these outcomes may reflect limitations in trial design, new, more potent antioxidant therapies are being pursued. Astaxanthin, a carotenoid found in microalgae, fungi, complex plants, seafood, flamingos and quail is one such agent. It has antioxidant and anti-inflammatory effects. Limited, short duration and small sample size studies have assessed the effects of astaxanthin on oxidative stress and inflammation biomarkers and have investigated bioavailability and safety. So far no significant adverse events have been observed and biomarkers of oxidative stress and inflammation are attenuated with astaxanthin supplementation. Experimental investigations in a range of species using a cardiac ischaemia-reperfusion model demonstrated cardiac muscle preservation when astaxanthin is administered either orally or intravenously prior to the induction of ischaemia. Human clinical cardiovascular studies using astaxanthin therapy have not yet been reported. On the basis of the promising results of experimental cardiovascular studies and the physicochemical and antioxidant properties and safety profile of astaxanthin, clinical trials should be undertaken.
Keywords: antioxidants; marine carotenoids; inflammation; oxidative stress; cardiovascular disease

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Fassett, R.G.; Coombes, J.S. Astaxanthin in Cardiovascular Health and Disease. Molecules 2012, 17, 2030-2048.

AMA Style

Fassett RG, Coombes JS. Astaxanthin in Cardiovascular Health and Disease. Molecules. 2012; 17(2):2030-2048.

Chicago/Turabian Style

Fassett, Robert G.; Coombes, Jeff S. 2012. "Astaxanthin in Cardiovascular Health and Disease." Molecules 17, no. 2: 2030-2048.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert